{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:09:38Z","timestamp":1762297778121,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T00:00:00Z","timestamp":1374278400000},"content-version":"vor","delay-in-days":658,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.acvd.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,10,16]],"date-time":"2011-10-16T02:12:06Z","timestamp":1318731126000},"page":"536-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Update on the medical treatment of stable angina"],"prefix":"10.1016","volume":"104","author":[{"given":"Jean-Louis","family":"Gayet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2011.08.001_bib0005","unstructured":"Aouba A, P\u00e9quignot F, Le Toullec A, et al. Num\u00e9ro th\u00e9matique\u00a0: surveillance \u00e9pid\u00e9miologique des causes de d\u00e9c\u00e8s en France. Les causes m\u00e9dicales de d\u00e9c\u00e8s en France en 2004 et leur \u00e9volution 1980-2004. Accessed 9 February 2011. http:\/\/www.invs.sante.fr\/beh\/."},{"key":"10.1016\/j.acvd.2011.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","article-title":"Guidelines on the management of stable angina pectoris: executive summary. The task force on the management of stable angina pectoris of the European Society of Cardiology","volume":"27","author":"Fox","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0015","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.107.187930","volume":"116","author":"Fraker","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2011.08.001_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.acvd.2009.05.003","article-title":"Heart rate distribution and predictors of increased heart rate among French hypertensive patients with stable coronary artery disease. Data from the LHYCORNE cohort","volume":"102","author":"Lorgis","year":"2009","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2011.08.001_bib0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.acvd.2010.05.002","article-title":"Distribution of left ventricular ejection fraction and heart rate values in a cohort of stable coronary patients: the INDYCE registry","volume":"103","author":"Tabet","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2011.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4065\/mcp.2009.0391","article-title":"Chronic coronary artery disease: diagnosis and management","volume":"84","author":"Cassar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.acvd.2011.08.001_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11886-008-0044-y","article-title":"The evolving role of medical therapy for chronic stable angina","volume":"10","author":"Eid","year":"2008","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.acvd.2011.08.001_bib0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/VHRM.S11100","article-title":"Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization","volume":"6","author":"Kones","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.acvd.2011.08.001_bib0045","unstructured":"O\u2019Toole L. Angina (chronic stable). Clin Evid (Online) 2008; 2008."},{"key":"10.1016\/j.acvd.2011.08.001_bib0050","doi-asserted-by":"crossref","unstructured":"Palaniswamy C, Aronow WS. Treatment of stable angina pectoris. Am J Ther 2010.","DOI":"10.1097\/MJT.0b013e3181f2ab9d"},{"key":"10.1016\/j.acvd.2011.08.001_bib0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0140-6736(10)60168-7","article-title":"Management of stable coronary artery disease","volume":"375","author":"Pfisterer","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0060","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0065","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jacc.2009.10.062","article-title":"Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial","volume":"55","author":"Maron","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJM199912093412415","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease","volume":"341","author":"Cohen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0080","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.109.911669","article-title":"Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease","volume":"122","author":"Hueb","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2011.08.001_bib0085","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0090","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurheartj\/ehp605","article-title":"Controversies in cardiovascular medicine: chronic stable coronary artery disease: drugs vs. revascularization","volume":"31","author":"Simoons","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1472-8206.2009.00769.x","article-title":"Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis","volume":"24","author":"Lievre","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"Twenty four-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2011.08.001_bib0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/VHRM.S9087","article-title":"Aspirin and clopidogrel resistance: methodological challenges and opportunities","volume":"6","author":"Gasparyan","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.acvd.2011.08.001_bib0110","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0115","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehq133","article-title":"Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?","volume":"31","author":"Deanfield","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0125","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0130","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2011.08.001_bib0135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the Efficacy of Ranolazine in Chronic Angina (ERICA) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0140","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0145","doi-asserted-by":"crossref","unstructured":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002; 359:1269\u201375.","DOI":"10.1016\/S0140-6736(02)08265-X"},{"issue":"Spec No. 2","key":"10.1016\/j.acvd.2011.08.001_bib0150","first-page":"43","article-title":"Beta-blocker therapy in acute myocardial infarction","volume":"91","author":"Danchin","year":"1998","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.acvd.2011.08.001_bib0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199802193380807","article-title":"Nitrate therapy for stable angina pectoris","volume":"338","author":"Parker","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0160","first-page":"745","article-title":"The effect of nitroglycerin on myocardial blood flow in various segments characterized by rest-redistribution thallium SPECT","volume":"44","author":"Tadamura","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9343(83)90858-6","article-title":"Nitroglycerin and long-acting nitrates in clinical practice","volume":"74","author":"Abrams","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF00053031","article-title":"Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina and heart failure","volume":"10","author":"Thadani","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2011.08.001_bib0175","doi-asserted-by":"crossref","first-page":"37M","DOI":"10.1016\/j.amjcard.2005.07.010","article-title":"Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors","volume":"96","author":"Carson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0180","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2165\/00003495-200161120-00002","article-title":"Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil","volume":"61","author":"Gomma","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.acvd.2011.08.001_bib0185","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2165\/00003495-200060040-00007","article-title":"Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects","volume":"60","author":"Markham","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.acvd.2011.08.001_bib0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1472-8206.2003.00154.x","article-title":"Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine","volume":"17","author":"Stanley","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0195","doi-asserted-by":"crossref","unstructured":"Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005:CD003614.","DOI":"10.1002\/14651858.CD003614.pub2"},{"key":"10.1016\/j.acvd.2011.08.001_bib0200","unstructured":"Commission nationale de pharmacovigilance. Compte rendu de la r\u00e9union du mardi 19 mai 2009. Accessed 4 July 2011. http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/61c6847bb097168d0bfe266d5515ec7b.pdf."},{"key":"10.1016\/j.acvd.2011.08.001_bib0205","unstructured":"R\u00e9union de la Commission d\u2019AMM du 7 avril 2011. Accessed 4 July 2011. http:\/\/www.afssaps.fr\/Activites\/Expertise\/Commissions-et-groupes-de-travail\/Commission-d-autorisation-de-mise-sur-le-marche\/Reunion-de-la-commission-d-AMM-du-07-avril-2011\/(language)\/fre-FR."},{"key":"10.1016\/j.acvd.2011.08.001_bib0210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2011.08.001_bib0215","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0220","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1054-3589(10)59003-3","article-title":"I(f) inhibition in cardiovascular diseases","volume":"59","author":"Thollon","year":"2010","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0235","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1167\/iovs.08-2659","article-title":"Selective Hcn1 channels inhibition by ivabradine in mouse rod photoreceptors","volume":"50","author":"Demontis","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.acvd.2011.08.001_bib0240","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1592\/phco.27.12.1659","article-title":"Ranolazine: a new option in the management of chronic stable angina","volume":"27","author":"Dobesh","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.acvd.2011.08.001_bib0245","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(08)61554-8","article-title":"Ranolazine for chronic stable angina","volume":"372","author":"Nash","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0250","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/TCRM.S4468","article-title":"Emerging clinical role of ranolazine in the management of angina","volume":"6","author":"Vadnais","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.acvd.2011.08.001_bib0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2011.08.001_bib0260","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0265","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes (MERLIN-TIMI) 36 Trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0270","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commisssion de transparence du 4 novembre 2009. Accessed 4 July 2011. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2009-11\/ranexa ct-6981.pdf."},{"key":"10.1016\/j.acvd.2011.08.001_bib0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/qjmed\/94.6.301","article-title":"Are patients suffering from stable angina receiving optimal medical treatment?","volume":"94","author":"Beaulieu","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.acvd.2011.08.001_bib0280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.amjmed.2004.02.044","article-title":"Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting","volume":"117","author":"Wiest","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2011.08.001_bib0285","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/eurheartj\/ehl005","article-title":"The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina","volume":"27","author":"Daly","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2011.08.001_bib0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/qjmed\/hcq011","article-title":"Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?","volume":"103","author":"Elder","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.acvd.2011.08.001_bib0295","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2011.08.001_bib0300","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/CIRCULATIONAHA.109.905687","volume":"122","author":"Bangalore","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2011.08.001_bib0305","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amjcard.2010.03.056","article-title":"Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST])","volume":"106","author":"Denardo","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2011.08.001_bib0310","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Guide affection de longue dur\u00e9e. Maladie coronarienne. Accessed 9 February 2010. http:\/\/www.has-sante.fr\/portail\/jcms\/c_534304\/ald-n13-maladie-coronarienne."}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213611002713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213611002713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:39:31Z","timestamp":1761745171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213611002713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1875213611002713"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2011.08.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the medical treatment of stable angina","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2011.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}